Mead Johnson Misses Q2 Earnings by a Penny; Guides Low - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 11:35AM CDT
Mead Johnson (MJN) posted dismal financial numbers in the second quarter of 2015, missing the Zacks Consensus Estimate on both lines
MJN: 89.20 (-0.69), RMTI: 8.05 (-0.05), NUVA: 62.20 (+0.18)
Medtronic Launches GenCut Lung Cancer Biopsy System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 16, 1:20PM CDT
Medtronic's (MDT) GenCut system enables pulmonologists and thoracic surgeons to collect multiple core samples from lesions deep inside the lungs.
MDT: 87.63 (+0.21), RMTI: 8.05 (-0.05), NUVA: 62.20 (+0.18)
Will Mead Johnson's Weak Q2 Preliminary Sales Hurt Growth? (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 3:34PM CDT
Mead Johnson Nutrition Company (MJN) recently released its preliminary results for the second quarter of 2015, which was followed by a revised guidance pertaining to the company's full-year 2015 financial performance.
MJN: 89.20 (-0.69), RMTI: 8.05 (-0.05), NUVA: 62.20 (+0.18)
Will Mead Johnson's Weak Q2 Preliminary Sales Hurt Growth? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 1:20PM CDT
Per the preliminary results, Mead Johnson's (MJN) second-quarter 2015 sales performance appears quite bleak.
MJN: 89.20 (-0.69), RMTI: 8.05 (-0.05), NUVA: 62.20 (+0.18)